X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs STERLING BIOTECH - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB STERLING BIOTECH DR. REDDYS LAB/
STERLING BIOTECH
 
P/E (TTM) x 32.0 -0.4 - View Chart
P/BV x 3.4 0.0 24,402.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   STERLING BIOTECH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
STERLING BIOTECH
Dec-13
DR. REDDYS LAB/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,78811 26,552.4%   
Low Rs1,9023 55,932.4%   
Sales per share (Unadj.) Rs860.826.8 3,211.0%  
Earnings per share (Unadj.) Rs57.1-15.0 -381.5%  
Cash flow per share (Unadj.) Rs122.0-5.5 -2,233.2%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.754.9 1,380.7%  
Shares outstanding (eoy) m165.91267.87 61.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.70.3 1,050.7%   
Avg P/E ratio x41.1-0.5 -8,842.7%  
P/CF ratio (eoy) x19.2-1.3 -1,510.8%  
Price / Book Value ratio x3.10.1 2,443.7%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0341,862 20,896.7%   
No. of employees `00023.51.4 1,737.4%   
Total wages/salary Rs m32,149547 5,879.5%   
Avg. sales/employee Rs Th6,070.85,303.3 114.5%   
Avg. wages/employee Rs Th1,366.6403.8 338.4%   
Avg. net profit/employee Rs Th402.5-2,959.0 -13.6%   
INCOME DATA
Net Sales Rs m142,8107,181 1,988.8%  
Other income Rs m1,55243 3,643.2%   
Total revenues Rs m144,3627,223 1,998.6%   
Gross profit Rs m23,512947 2,483.0%  
Depreciation Rs m10,7722,543 423.6%   
Interest Rs m7884,377 18.0%   
Profit before tax Rs m13,504-5,931 -227.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380-1,924 -227.6%   
Profit after tax Rs m9,468-4,007 -236.3%  
Gross profit margin %16.513.2 124.9%  
Effective tax rate %32.432.4 100.0%   
Net profit margin %6.6-55.8 -11.9%  
BALANCE SHEET DATA
Current assets Rs m104,98414,335 732.4%   
Current liabilities Rs m68,93849,809 138.4%   
Net working cap to sales %25.2-494.0 -5.1%  
Current ratio x1.50.3 529.2%  
Inventory Days Days74403 18.4%  
Debtors Days Days104171 60.7%  
Net fixed assets Rs m104,38555,432 188.3%   
Share capital Rs m830268 309.8%   
"Free" reserves Rs m124,88613,935 896.2%   
Net worth Rs m125,71614,701 855.1%   
Long term debt Rs m25,0899,478 264.7%   
Total assets Rs m225,44373,988 304.7%  
Interest coverage x18.1-0.4 -5,109.6%   
Debt to equity ratio x0.20.6 31.0%  
Sales to assets ratio x0.60.1 652.7%   
Return on assets %4.50.5 908.2%  
Return on equity %7.5-27.3 -27.6%  
Return on capital %9.7-6.4 -151.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m72,6231,860 3,904.9%   
Fx outflow Rs m18,91625 75,998.4%   
Net fx Rs m53,7071,835 2,927.0%   
CASH FLOW
From Operations Rs m18,0301,719 1,049.0%  
From Investments Rs m-14,883-3,148 472.7%  
From Financial Activity Rs m-4,4401,426 -311.4%  
Net Cashflow Rs m-1,236-3 36,352.9%  

Share Holding

Indian Promoters % 25.5 33.9 75.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.0 -  
FIIs % 35.3 9.9 356.6%  
ADR/GDR % 18.5 16.9 109.5%  
Free float % 15.3 39.3 38.9%  
Shareholders   75,885 21,482 353.2%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS